CYCN News and Press, Cyclerion Therapeutics Inc. From 09/10/19

CAMBRIDGE, Mass., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced that it wi...

Cyclerion Therapeutics ( CYCN ) Q2 results : Revenues: $1.6M. More news on: Cyclerion Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, , Read more ...

Cyclerion Therapeutics (NASDAQ: CYCN ): Q2 GAAP EPS of -$1.18 misses by $0.34 . More news on: Cyclerion Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

– Two praliciguat Phase 2 studies for diabetic nephropathy and heart failure with preserved ejection fraction (HFpEF) on track for data readouts in Q4 2019 – – Phase 2 study of olinciguat in sickle cell disease on track for data readout in mid-2020 – ...

– Series of preclinical studies provide further rationale for study of IW-6463 as a potential treatment for neurodegenerative diseases –              – Preclinical data provide insights int...

– In preclinical study, treatment with company’s investigational sGC stimulator olinciguat was associated with improved blood flow and reduced inflammation in a model of sickle cell disease – – New research supports the need for a novel patient-reporte...

Gainers:  Genocea Biosciences (NASDAQ: GNCA ) +45% . Mirati Therapeutics (NASDAQ: MRTX ) +34% . Cypress Semiconductor (NASDAQ: CY ) +25% . ARCA biopharma (NASDAQ: ABIO ) +23% . Centrus Energy (NYSEMKT: LEU ) +18% . Spirit MTA REIT (NYSE: SMTA ) +18% . El Paso Electric (NYSE: EE ...

– Completed enrollment in Phase 2 studies of praliciguat in diabetic nephropathy and heart failure with preserved ejection fraction (HFpEF) – – Based on encouraging tolerability data, company intends to add a higher olinciguat dose level to the Phase 2 sickle c...

Cyclerion Therapeutics ( CYCN ) is a recent spin off from Ironwood Pharmaceuticals ( IRWD ) that caught my attention after President Mark Currie acquired over 270,000 shares (paid $14.81 for total of around $4 million). Keep in mind Mr. Currie already had received 51,648 shares via the actua...

CAMBRIDGE, Mass., April 25, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced that it wi...